Abstract
No universal guidelines exist on Disease-Modifying Therapies (DMTs) use in people with Secondary Progressive Multiple Sclerosis (SPMS). The aim is to investigate in a large cohort of patients with a diagnosis of SPMS after at least two years of non-relapsing MS, the ability of DMTs in delaying disability accrual, expressed as the time to 24-week confirmed Expanded Disability Status Scale (EDSS) ≥7.0.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
